Abstract
Despite premature mortality of still approximately twice that in the general population, the increase in mean lifespan of people suffering from schizophrenia and the specific clinical and management features of this disorder raise questions in our practice and present us with a dual challenge. Firstly we need to better characterise these elderly patients by conducing specific rigorous studies, epidemiological, clinical, pharmacological and cognitive. In parallel it would seem essential to precisely quantify the current specialist care offered in receiving, assessing and managing these patients in order to be able to develop the most appropriate alternative structures and best meet this true public health challenge.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
